January 31, 2017.
Australian researchers have just made a discovery that could revolutionize the treatment of idiopathic pulmonary fibrosis, using shark antibodies.
Shark antibodies to stop the progression of idiopathic pulmonary fibrosis
Scientific research against idiopathic pulmonary fibrosis (FIP) has undoubtedly just taken a giant leap forward, spearheaded by Australian researchers. Their latest discoveries bring real hope to patients affected by this disease, the exact origin of which is still unknown today.
These scientists from the University of Melbourne have in fact discovered thatan antibody, present in the body of sharks, could kill and stop the progression of cells which are at the origin of this pathology. From this discovery was born a drug, called AD-114, which should be tested, in vivo, on patients with FIP, starting next year.
Idiopathic pulmonary fibrosis, an incurable disease
To speed up the clinical study process, the US Food and Drug Administration has decided to give this molecule the status of “orphan drug”. A statute which allows the laboratory behind the drug, the biotechnology company AdAlta, to benefit from tax favors to carry out research.
Idiopathic pulmonary fibrosis is an incurable disease. Patients with this syndrome see their lung functions decrease over time due to progressive stiffening of their lungs.
Sybille Latour
